Activity of cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations on Enterobacter cloacae complex and Klebsiella aerogenes in Spain (SMART 2016-2022).
Ángel Rodríguez-Villodres, Esperanza Lepe-Balsalobre, José Manuel Ortiz De La Rosa, Salvador Giner Almaraz, Elisa González De Herrero, Emilia Cercenado, Sergio García-Fernández, Rafael Benito, Ricardo Ponz Mir, Rafael Cantón, José Antonio Lepe
{"title":"Activity of cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations on <i>Enterobacter cloacae</i> complex and <i>Klebsiella aerogenes</i> in Spain (SMART 2016-2022).","authors":"Ángel Rodríguez-Villodres, Esperanza Lepe-Balsalobre, José Manuel Ortiz De La Rosa, Salvador Giner Almaraz, Elisa González De Herrero, Emilia Cercenado, Sergio García-Fernández, Rafael Benito, Ricardo Ponz Mir, Rafael Cantón, José Antonio Lepe","doi":"10.1093/jacamr/dlae087","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To analyse the susceptibility profile to cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations in <i>Enterobacter cloacae</i> complex and <i>Klebsiella aerogenes</i> isolated from intra-abdominal, urinary, respiratory and bloodstream infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain.</p><p><strong>Methods: </strong>The susceptibilities of 759 isolates (473 <i>E. cloacae</i> complex and 286 <i>K. aerogenes</i>) collected in 11 Spanish hospitals from 2016 to 2022 were analysed following the EUCAST 2023 criteria. Molecular characterization looking for β-lactamase genes was performed through PCR and DNA sequencing analysis.</p><p><strong>Results: </strong><i>E. cloacae</i> complex showed resistance to third-generation cephalosporins in 25% of the cases, whereas <i>K. aerogenes</i> was resistant in 35%. Regarding cefepime, resistance in <i>E. cloacae</i> was higher (10%) than in <i>K. aerogenes</i> (2%). Carbapenems showed >85% activity in both microorganisms. Ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam had good activity against these microorganisms (>95%). In contrast, the activity of ceftolozane/tazobactam was lower (80%). A high proportion of the isolates resistant to new β-lactam/β-lactamase inhibitor combinations carried a carbapenemase, mainly OXA-48-like and VIM-1.</p><p><strong>Conclusions: </strong>Ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam show high activity against both <i>E. cloacae</i> complex and <i>K. aerogenes</i> isolates recovered in the SMART-Spain study. In contrast, differences have been found in the case of cefepime, showing more activity against <i>K. aerogenes</i> than <i>E. cloacae</i> complex. These results are useful for antimicrobial stewardship programmes and for the implementation of local and national guidelines.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 3","pages":"dlae087"},"PeriodicalIF":3.7000,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11154015/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To analyse the susceptibility profile to cefepime, carbapenems and new β-lactam/β-lactamase inhibitor combinations in Enterobacter cloacae complex and Klebsiella aerogenes isolated from intra-abdominal, urinary, respiratory and bloodstream infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain.
Methods: The susceptibilities of 759 isolates (473 E. cloacae complex and 286 K. aerogenes) collected in 11 Spanish hospitals from 2016 to 2022 were analysed following the EUCAST 2023 criteria. Molecular characterization looking for β-lactamase genes was performed through PCR and DNA sequencing analysis.
Results: E. cloacae complex showed resistance to third-generation cephalosporins in 25% of the cases, whereas K. aerogenes was resistant in 35%. Regarding cefepime, resistance in E. cloacae was higher (10%) than in K. aerogenes (2%). Carbapenems showed >85% activity in both microorganisms. Ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam had good activity against these microorganisms (>95%). In contrast, the activity of ceftolozane/tazobactam was lower (80%). A high proportion of the isolates resistant to new β-lactam/β-lactamase inhibitor combinations carried a carbapenemase, mainly OXA-48-like and VIM-1.
Conclusions: Ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam show high activity against both E. cloacae complex and K. aerogenes isolates recovered in the SMART-Spain study. In contrast, differences have been found in the case of cefepime, showing more activity against K. aerogenes than E. cloacae complex. These results are useful for antimicrobial stewardship programmes and for the implementation of local and national guidelines.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
